a Ophthalmology Department , São Paulo Federal University , São Paulo , Brazil.
Ocul Immunol Inflamm. 2018;26(7):1041-1044. doi: 10.1080/09273948.2017.1307420. Epub 2017 Apr 27.
To evaluate intravitreal injections of sulfamethoxazole/trimethoprim in association with dexamethasone for treating toxoplasmic retinochoroiditis.
Thirteen patients with active, recurrent ocular focal toxoplasmic retinochoroiditis and visual acuity worse than 20/63 in the affected eye were included. Ocular toxoplasmosis was diagnosed according to the classic clinical findings. The primary end point was the change in the final best-corrected visual acuity (BCVA).
The intraocular inflammation decreased within 2 weeks after injection in all eyes and resolved in 8 (62%) eyes with only one injection after 30 days; the remaining eyes received two injections. In all eyes, the retinitis was inactive and no patient had decreased early treatment diabetic retinopathy study lines of BCVA at the final examination.
The combination of intravitreal trimethoprim/sulfamethoxazole and dexamethasone might be an alternative treatment strategy in patients with toxoplasmic retinochoroiditis.
评估甲氨蝶呤/磺胺甲恶唑联合地塞米松玻璃体腔内注射治疗弓形虫性视网膜炎。
纳入 13 例活动期、复发性眼局部弓形虫视网膜炎且患眼最佳矫正视力（BCVA）低于 20/63 的患者。眼弓形体病的诊断依据为典型的临床发现。主要终点是最终最佳矫正视力（BCVA）的变化。
所有患者在注射后 2 周内眼内炎症均有所减轻，30 天后 8 只眼（62%）仅注射 1 次即可消退；其余眼接受了 2 次注射。所有眼的视网膜炎均处于不活动状态，最终检查时无患者的早期治疗糖尿病视网膜病变研究视力 BCVA 下降。
对于弓形虫性视网膜炎患者，玻璃体内注射甲氧苄啶/磺胺甲恶唑联合地塞米松可能是一种替代治疗策略。
